University of Toronto

Roche Diagnostics Operations, Inc.

Other

Engineering Services Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Andrew Emili

Georg Hess

Ursula-Henrike Wienhues-Thelen

Dirk Block

Anthony Gramolini

Peter Liu

David MacLennan

Herbert Von Der Eltz

Sachdev Singh Sidhu

Hendrik Huedig

Kyrylo Zagorovsky

Warren C W Chan

Vincent Fong

Jonathan Buchanan Olsen

Megan McLaughlin

Thomas Kislinger

Ruth Isserlin

Pawel Kuzan

Sara Arab

Hendrik Heudig

David Maclennan

The invention describes methods and reagents useful for sequencing polypeptide molecules. The method comprises affixing a polypeptide to a substrate and contacting the polypeptide with a plurality of probes. Each probe selectively binds to an N-terminal amino acid or an N-terminal amino acid derivative. Probes bound to the polypeptide molecule are then identified before cleaving the N-terminal amino acid or N-terminal amino acid derivative of the polypeptide. Also provided are methods for the sequencing a plurality of polypeptide molecules in a sample and probes specific for N-terminal amino acids or N-terminal amino acid derivatives.

Protein sequencing method and reagents

Described are optical methods and reagents for sequencing polypeptides. A probe that exhibits different spectral properties when conjugated to different N-terminal amino acids is conjugated to the N-terminal amino acid of a polypeptide. Sequentially detecting one or more spectral properties of the probe conjugated to the N-terminal amino acid and cleaving the N-terminal amino acid produces sequence information of the polypeptide. The use of super-resolution microscopy allows for the massively parallel sequencing of individual polypeptide molecules in situ such as within a cell. Also described are probes comprising hydroxymethyl rhodamine green, an isothiocyanate group and a protecting group.

Protein sequencing methods and reagents

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.

Use of IGFBP-7 in the assessment of heart failure

The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.

Use of SLIM-1 in the assessment of heart failure

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.

Use of SFRP-3 in the assessment of heart failure

There is provided a method for the identification of macromolecule targets of analytes such as drugs in biological samples comprising complex mixtures of macromolecules. A biological sample is contacted with one or more analyte and the mixture is resolved such that the analyte and its target are co-eluted and analyzed to identify analyte-target complexes.

Method for the identification of macromolecule targets of analytes

An automatic sample loader is for use in association with a mass spectrometer and at least one vial containing a sample. The loader includes a vial block, an insertion head, an insertion tube, a mechanism for pushing the sample out of the vial and a mechanism for moving the insertion head relative to the vial. The vial block has at least one vial cavity and each vial cavity is adapted to receive a vial. The insertion head is adapted to be sealingly engageable in the vial cavity. The insertion tube is operably connected to the mass spectrometer through the insertion head, such that the tube extends into the vial when the insertion head is sealingly engaged in the vial cavity. The pushing mechanism is adapted to push the sample out of the vial and into the tube. The moving mechanism is adapted to move the insertion head relative to the vial block from an engaged position to a disengaged position.

Automatic sample loader for use with a mass spectrometer

Growing community of inventors

Toronto, Canada

Andrew Emili